Role of nabilone in CINV Razavi D, Delvaux N, Farvacques C, et al. 1993. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol, 11:1384–90. Roscoe JA, Morrow GR, Hickok JT, et al. 2000. Nausea and vomiting remain a signiﬁcant clinical problem: J Pain Symptom Mange, 20:113–21. Schlicker E, Kathmann M. 2001. Modulation of transmitter release via pre- synaptic cannabinoid receptors. Trends Pharmacol Sci, 22:565–72. Schwartzberg L. 2006. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol, (suppl 1):3–8. Shakespeare DT, Boggild M, Young C. 2003. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev, CD001332. Stockhorst U, Klosterhalfen S, Klosterhalfen W, et al. 1993. Anticipatory nausea in cancer patients receiving chemotherapy: classical condition- ing etiology and therapeutical implications. Integr Physiol Behav Sci, 28: 177–81. Strasser F, Luftner D, Possinger K, et al. 2006. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol, 24:3394–400. Sun CC, Bodurka DC, Weaver CB, et al. 2004. Rankings and symptom assessments of side effects from chemotherapy: insights from experi- enced patients with ovarian cancer. Support Care Cancer, 13:219–27. Tramér MR, Carroll D, Campbell FA, et al. 2001. Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ, 323:1–8. Vanscoy GJ, Fortner B, Smith R, et al. 2005. Preventing chemotherapy- induced nausea and vomiting: the economic implications of choosing antiemetics. Commun Oncol, 2:127–132. Vinciguerra V, Moore T, Brennan E. 1988. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med, 88:525–7. Waknine Y. 2006. FDA approvals: Lumigan, Cesamet, Omnitrope. Med- scape Medical News. July 14, 2006. Accessed 9 September 2006. URL: http://www.medscape.com/viewarticle/540937. Ward A, Holmes B. 1985. Nabilone. A preliminary review of its pharmaco- logical properties and therapeutic use. Drugs, 30:127–44. Wiser W, Berger A. 2005. Practical management of chemotherapy-induced nausea and vomiting. Oncology, 19:637–45. Wissel J, Haydn, Muller J, et al. 2006. Low dose treatment with the syn- thetic cannabinoid nabilone signiﬁcantly reduces spasticity-related pain. A double-blind placebo-controlled cross-over trial. J Neurol, 20:2218–20. Therapeutics and Clinical Risk Management 2008:4(1) 107